eEF2K Is a Poor Prognostic Factor and Novel Molecular Target in Pancreatic Cancer: Regulating Tumor Growth and Progression via the Tumor Microenvironment

eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progression via the tumor microenvironment

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with an average survival time of only six months following diagnosis, even with currently available therapies. Thus, PDAC represents a significant therapeutic challenge, necessitating a deeper understanding of its biology and tumor microenvironment (TME) to develop more effective treatments and improve patient outcomes. Here, we report that the expression of Eukaryotic El…

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Ca

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess

eEF2K Is a Poor Prognostic Factor and Novel Molecular Target in Pancreatic Cancer: Regulating Tumor Growth and Progression Via the Tumor Microenvironment

Researchers reported that the expression of eukaryotic elongation factor-2 kinase (eEF2K) is associated with shorter patient survival and demonstrated that eEF2K signaling is critical for the PDAC tumor growth and is regulated by the tumor microenvironment. [Cell Death & Disease] Full Article